Johnson & Johnson announced Phase 1b/2 results from the open-label OrigAMI-4 study evaluating investigational subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus the PD-1 inhibitor pembrolizumab as first-line treatment for PD-L1-positive, HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma. In Cohort 2, the confirmed overall response rate was 56% (22/39; 95% CI 40–72), including six complete responses (10% complete response rate at the time of analysis), with median progression-free survival of 7.7 months; median overall survival was not estimable at the data cutoff. The company said the data were presented during a plenary session at the 2026 Multidisciplinary Head and Neck Cancers Symposium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191700PR_NEWS_USPR_____NY90526) on February 19, 2026, and is solely responsible for the information contained therein.